03:11 , Jan 13, 2018 |  BioCentury  |  Finance

JPM jolt

Fifteen biotechs that presented at the 2018 J.P. Morgan Healthcare Conference posted gains of at least 15%, with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) leading the risers after announcing that its board rejected two unsolicited acquisition proposals...
21:39 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

QIMR reports updated Phase I data for MS candidate

Atara Biotherapeutics Inc. (NASDAQ:ATRA) said QIMR Berghofer Medical Research Institute (Brisbane, Australia) reported updated data from a Phase I trial in 10 patients with primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS) showing...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

MVA-EBNA/LMP2 vaccine: Phase Ib started

Cancer Research UK said its Drug Development Office ( DDO) began a U.K. Phase Ib trial to evaluate 3 doses of intradermal MVA-EBNA/LMP2 vaccine every 3 weeks followed by another dose 12 weeks later in...